Summary of Identiv's Q3 2025 Earnings Call

1Key Financial Results and Metrics

Revenue: $5 million, down from $6.5 million in Q3 2024, as anticipated due to exiting lower-margin business.

Gross Margins: GAAP gross margin at 10.7% and non-GAAP gross margin at 19.1%, a significant improvement from 3.6% and 60.3% in Q3 2024, attributed to the transition to the Thailand facility.

Operating Expenses: GAAP operating expenses were $6.1 million, down from $9.8 million in Q3 2024; non-GAAP operating expenses were $4.5 million, down from $5.1 million.

Net Loss: GAAP net loss from continuing operations was $3.5 million ($0.15 per share), improved from a loss of $9.3 million ($0.40 per share) in Q3 2024.

Adjusted EBITDA: Non-GAAP adjusted EBITDA loss was $3.6 million, an improvement from $4.5 million in Q3 2024.

Cash Position: Ended Q3 with $126.6 million in cash and equivalents, with $3.1 million cash used in the quarter.

2Strategic Updates and Business Highlights

Manufacturing Transition: Completed the transition of production to a new facility in Thailand, expected to enhance efficiency and lower costs.

New Product Development (NPD): 17 active NPD projects, with a focus on healthcare and BLE technology, including partnerships with Williot and Lilly.

Sales Pipeline: 108 new opportunities in the pipeline, with a conversion rate of 18% year-to-date, contributing to 10% of Q3 sales.

Operational Initiatives: Launched CRM and MRP automation to streamline operations, with expected implementation by year-end.

3Forward Guidance and Outlook

Q4 2025 Revenue Guidance: Expected to be between $5.4 million and $5.9 million, reflecting anticipated growth from existing customers and new BLE projects.

Margin Expectations: Continued improvement in gross margins anticipated as the Singapore site shutdown is completed and the Thailand facility reaches full productivity.

4Bad News, Challenges, or Points of Concern

Revenue Decline: Year-over-year revenue decrease due to strategic exits from lower-margin business segments.

Operational Costs: Some residual costs from the Singapore facility will still impact Q4 margins until fully shut down.

Longer Sales Cycles: Healthcare-related projects are progressing slower compared to logistics and consumer products, which may delay revenue recognition.

5Notable Q&A Insights

Growth Drivers: CEO Kirsten Newquist indicated that growth in Q4 would come from existing channel customers and traction from BLE projects.

Volume Shipments: Progress on IFCo and Williot projects is on track, with expectations for volume shipments in the second half of 2026.

High Margin Opportunities: Approximately two-thirds of converted opportunities are expected to exceed the company's 20% gross margin goal.

Healthcare Focus: The company remains optimistic about healthcare opportunities, though they are longer-term compared to other segments. Overall, Identiv reported steady progress in Q3 2025, with improvements in gross margins and operational efficiency, while navigating challenges related to revenue decline and longer sales cycles in certain segments. The strategic focus remains on enhancing product offerings and expanding into high-value markets.